Related references
Note: Only part of the references are listed.Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial
Stephen J. Nicholls et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2016)
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham et al.
ATHEROSCLEROSIS (2016)
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
Jae-Seok Roe et al.
MOLECULAR CELL (2015)
Complement system part II: role in immunity
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
Complement system part I - molecular mechanisms of activation and regulation
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes
Chun Hin Chan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
Ravi Jahagirdar et al.
ATHEROSCLEROSIS (2014)
C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors
Bo Nilsson et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Complement activation products C5a and sC5b-9 are associated with low-grade inflammation and endothelial dysfunction, but not with atherosclerosis in a cross-sectional analysis: The CODAM study
E. Hertle et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Jonathan D. Brown et al.
MOLECULAR CELL (2014)
The complement system in human cardiometabolic disease
E. Hertle et al.
MOLECULAR IMMUNOLOGY (2014)
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Z. Zou et al.
ONCOGENE (2014)
Hepatic nuclear factor 4α positively regulates complement C3 expression and does not interfere with TNFα-mediated stimulation of C3 expression in HepG2 cells
Vladimir S. Shavva et al.
GENE (2013)
Peroxisome Proliferator-activated Receptor α Positively Regulates Complement C3 Expression but Inhibits Tumor Necrosis Factor α-mediated Activation of C3 Gene in Mammalian Hepatic-derived Cells
Denis A. Mogilenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Mice Lacking C1q Are Protected from High Fat Diet-induced Hepatic Insulin Resistance and Impaired Glucose Homeostasis
Antoinette D. Hillian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
Anna C. Belkina et al.
JOURNAL OF IMMUNOLOGY (2013)
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
Kevin G. McLure et al.
PLOS ONE (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
Soren Lindberg et al.
AMERICAN HEART JOURNAL (2012)
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies
Stephen J. Nicholls et al.
CARDIOVASCULAR DRUGS AND THERAPY (2012)
Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure
Timea Gombos et al.
CLINICAL RESEARCH IN CARDIOLOGY (2012)
Hepatic acute phase proteins - Regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling
Johannes G. Bode et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2012)
Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition
Guangtao Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors
Hozefa S. Bandukwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Complement Activation: An Emerging Player in the Pathogenesis of Cardiovascular Disease
Angela M. Carter
SCIENTIFICA (2012)
Complement C3 and cleavage products in cardiometabolic risk
Altan Onat et al.
CLINICA CHIMICA ACTA (2011)
Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors
Terry W. Du Clos et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2011)
Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease A Randomized Controlled Trial
Stephen J. Nicholls et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a
Walter S. Speidl et al.
ATHEROSCLEROSIS (2010)
Molecular Intercommunication between the Complement and Coagulation Systems
Umme Amara et al.
JOURNAL OF IMMUNOLOGY (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Larry Gold et al.
PLOS ONE (2010)
The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration and Activation
Yael Mamane et al.
DIABETES (2009)
Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke:: a population-based cohort study
Gunnar Engstrom et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2007)
Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events
Anil Palikhe et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty
Walter S. Speidl et al.
JOURNAL OF ENDOVASCULAR THERAPY (2007)
Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis
WS Speidl et al.
EUROPEAN HEART JOURNAL (2005)
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans
S Hillebrandt et al.
NATURE GENETICS (2005)
Near completely humanized liver in mice shows human-type metabolic responses to drugs
C Tateno et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Comparative effects of cytokines and cytokine combinations on complement component C3 secretion by HepG2 cells
E Andrews et al.
CYTOKINE (2003)
The systemic reaction during inflammation: The acute-phase proteins
F Ceciliani et al.
PROTEIN AND PEPTIDE LETTERS (2002)
Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component
AJ Szalai et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
